| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | sodium valproate (Episenta®) |
| Formulation | 100 mg/ml solution for injection |
| Reference number | 2221 |
| Indication | Treatment of epileptic patients who would normally be maintained on oral sodium valproate but for whom oral therapy is temporarily not possible |
| Company | Desitin Pharma Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 24/05/2013 |